/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/0f2146bc-8a38-4a78-8fb8-fe1b37fb7287.jpg)
Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline creates strong cash flows and a narrow economic moat.
Sanofi SA ADR SNY
Bulls Say, Bears Say
Bulls
Immunology drug Dupixent holds strong pricing power and market share across several indications.
Bears
Sanofi suffered several disappointing readouts starting in 2025, adding pressure to develop or acquire assets that could replace Dupixent before its loss of exclusivity.
News
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe — Update
-
EU Seeks Views on Sanofi's Concessions to End Competition Probe
-
Sanofi Drug for Rare Neuromuscular Disease Hits Goals in Late-Stage Trial
-
Sanofi Probed by EU Over Flu Vaccine Marketing
-
Sanofi Multiple Sclerosis Drug Gets EU Approval — Update
-
Sanofi Multiple Sclerosis Drug Gets EU Approval
-
Sanofi Names New Pharma Research Head as CEO Moves to Speed Up Pipeline — Update
-
Sanofi Names New Pharma Research Head After Drug Setbacks
Articles & Videos
-
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus
-
9 New 5-Star Stocks This Week
-
18 of the Best Stocks and ETFs to Buy Based on 2026 Expert Forecasts
-
Best Sustainable Companies to Own: 2025 Edition
-
Best Healthcare Companies to Own: 2025 Edition
-
The Best Companies to Own: 2025 Edition
-
The Thrilling 33
-
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum?
Trading Information
- Previous Close Price
- $43.18
- Day Range
- $43.04–43.72
- 52-Week Range
- $40.89–52.68
- Bid/Ask
- $43.64 / $43.68
- Shares Outstanding
- 2.39B
- Market Cap
- $104.55B
- Volume/Avg
- 777,001 / 3M
Key Statistics
- Price/Earnings (Normalized)
- 10.25
- Price/Sales
- 1.92
- Dividend Yield (Trailing)
- 5.60%
- Dividend Yield (Forward)
- 5.60%
- Total Yield
- 10.92%
Company Profile
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 74,846
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNY
|
NVS
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.25 | 17.30 | 7.92 |
Price/Book Value | 1.24 | 7.45 | 1.53 |
Price/Sales | 1.92 | 5.15 | 2.19 |
Price/Cash Flow | 8.78 | 14.75 | 8.10 |
Price/Earnings
SNY
NVS
PFE
Financial Strength
|
Metric
|
SNY
|
NVS
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.20 | 0.53 | 0.85 |
Current Ratio | 1.01 | 0.85 | 1.25 |
Interest Coverage | 11.82 | 13.66 | 3.73 |
Quick Ratio
SNY
NVS
PFE
Profitability
|
Metric
|
SNY
|
NVS
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 7.49% | 15.46% | 8.40% |
Return on Equity (Normalized) | 13.70% | 39.95% | 19.47% |
Return on Invested Capital (Normalized) | 10.47% | 22.43% | 12.80% |
Return on Assets
SNY
NVS
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|&B$KrbG | LOCK|htX | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|pd#!^f | LOCK|@b% | $611B | |||
| AbbVie Inc
ABBV
| LOCK|#??><q# | LOCK|x@ | $432B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@rw^%JjX | LOCK|!m# | $320B | |||
| Merck & Co Inc
MRK
| LOCK|dT^$rn! | LOCK|#?# | $298B | |||
| Novartis AG ADR
NVS
| LOCK|yP@Jsj? | LOCK|kZ | $287B | |||
| AstraZeneca PLC
AZN
| LOCK|hj!v^lWM | LOCK|gCn | $256B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|d%S%Yb< | LOCK|&xM | $215B | |||
| Amgen Inc
AMGN
| LOCK|q!QxtK!> | LOCK|%Q | $192B | |||
| Gilead Sciences Inc
GILD
| LOCK|mQ>#mN% | LOCK|$$ | $161B |
United States